<?xml version="1.0" encoding="UTF-8" ?><?xml-stylesheet href="http://www.japancorp.net/rss/rss2full.xsl" type="text/xsl" media="screen"?><?xml-stylesheet href="http://www.japancorp.net/rss/itemcontent.css" type="text/css" media="screen"?><rss version="2.0"><channel><title>JCN Newswire</title><link>http://www.japancorp.net</link><description>JCN Newswire - Recent Headline News</description><language>en-us</language><copyright>Copyright 2012, JCN Newswire</copyright><ttl>10</ttl><image><title>JCN Newswire</title><url>http://www.japancorp.net/images/jcnxml.jpg</url><link>http://www.japancorp.net</link><width>88</width><height>31</height><description>JCN Newswire</description></image><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" href="http://www.japancorp.net/rss/h_health.xml" type="application/rss+xml" /><item><title>Eisai Launches Programs to Help Eliminate Lymphatic Filariasis By 2020</title><guid>http://www.japancorp.net/press_release/24806/eisai_launches_programs_to_help_eliminate_lymphatic_filariasis_by_2020</guid><link>http://www.japancorp.net/press_release/24806/eisai_launches_programs_to_help_eliminate_lymphatic_filariasis_by_2020</link><description>Eisai gave its support to the London Declaration, a coordinated effort to eliminate 10 neglected tropical disease by the end of this decade, in line with its commitment to aid the World Health Organization's lymphatic filariasis elimination program.</description><pubDate>Tue,31 Jan 2012 12:19:41 +0000</pubDate></item><item><title>Otsuka Pharmaceutical, UCB to Focus Collaboration on Central Nervous System Disorders</title><guid>http://www.japancorp.net/press_release/24755/otsuka_pharmaceutical_ucb_to_focus_collaboration_on_central_nervous_system_disorders</guid><link>http://www.japancorp.net/press_release/24755/otsuka_pharmaceutical_ucb_to_focus_collaboration_on_central_nervous_system_disorders</link><description>Otsuka Pharmaceutical and UCB will be focusing their collaboration on the therapeutic area of Central Nervous System disorders, while discontinuing their collaboration on immunology after an agreed upon transition period.</description><pubDate>Thu,19 Jan 2012 16:31:1 +0000</pubDate></item><item><title>Asahi Kasei Pharma Launches Flivas in South Korea</title><guid>http://www.japancorp.net/press_release/24732/asahi_kasei_pharma_launches_flivas_in_south_korea</guid><link>http://www.japancorp.net/press_release/24732/asahi_kasei_pharma_launches_flivas_in_south_korea</link><description>Asahi Kasei Pharma's licensing partner Dong-A has launched the sale of Flivas (naftopidil) in South Korea as an agent for the treatment of benign prostatic hyperplasia (BPH).</description><pubDate>Fri,13 Jan 2012 11:59:21 +0000</pubDate></item><item><title>Mazda Hospital Completes Construction of New Wing</title><guid>http://www.japancorp.net/press_release/24729/mazda_hospital_completes_construction_of_new_wing</guid><link>http://www.japancorp.net/press_release/24729/mazda_hospital_completes_construction_of_new_wing</link><description>The new hospital wing is a part of the hospital's renovation plans, designed to make a further contribution to the local community with medical services.</description><pubDate>Fri,13 Jan 2012 11:30:16 +0000</pubDate></item><item><title>Toray to Acquire Equity Stake in Mitsui Subsidiary MicroBiopharm</title><guid>http://www.japancorp.net/press_release/24693/toray_to_acquire_equity_stake_in_mitsui_subsidiary_microbiopharm</guid><link>http://www.japancorp.net/press_release/24693/toray_to_acquire_equity_stake_in_mitsui_subsidiary_microbiopharm</link><description>Toray Industries will be acquiring a 20% stake in Mitsui's wholly-owned subsidiary MicroBiopharm Japan.</description><pubDate>Thu,5 Jan 2012 19:58:42 +0000</pubDate></item><item><title>OMD Acquires Stake in Era</title><guid>http://www.japancorp.net/press_release/24683/omd_acquires_stake_in_era</guid><link>http://www.japancorp.net/press_release/24683/omd_acquires_stake_in_era</link><description>OMD has entered the endoscopic field by acquiring a stake in Italy's Era Endoscopy.</description><pubDate>Tue,3 Jan 2012 09:55:18 +0000</pubDate></item><item><title>Fujifilm to Acquire SonoSite</title><guid>http://www.japancorp.net/press_release/24679/fujifilm_to_acquire_sonosite</guid><link>http://www.japancorp.net/press_release/24679/fujifilm_to_acquire_sonosite</link><description>Fujifilm, through a U.S. subsidiary, will acquire SonoSite for approximately $995 million.</description><pubDate>Thu,29 Dec 2011 12:56:33 +0000</pubDate></item><item><title>Toray, Japan Tobacco and Torii Terminate the Joint Development of Nalfurafine Hydrochloride for Pruritus</title><guid>http://www.japancorp.net/press_release/24664/toray_japan_tobacco_and_torii_terminate_the_joint_development_of_nalfurafine_hydrochloride_for_pruritus</guid><link>http://www.japancorp.net/press_release/24664/toray_japan_tobacco_and_torii_terminate_the_joint_development_of_nalfurafine_hydrochloride_for_pruritus</link><description>Toray, Japan Tobacco and Torii Pharmaceutical have agreed to discontinue the joint development program of nalfurafine hydrochloride.</description><pubDate>Tue,27 Dec 2011 10:32:18 +0000</pubDate></item><item><title>Mitsui to Acquire Stake in Turkish Healthcare Group</title><guid>http://www.japancorp.net/press_release/24656/mitsui_to_acquire_stake_in_turkish_healthcare_group</guid><link>http://www.japancorp.net/press_release/24656/mitsui_to_acquire_stake_in_turkish_healthcare_group</link><description>Mitsui has agreed to an acquisition of shares in the holding company for Turkish private healthcare group Acibadem by IHHSB, in which Mitsui holds a 30% stake through its subsidiary MBKHP.</description><pubDate>Mon,26 Dec 2011 11:30:34 +0000</pubDate></item><item><title>Asahi Kasei Pharma Launches Osteoporosis Drug in Japan</title><guid>http://www.japancorp.net/press_release/24578/asahi_kasei_pharma_launches_osteoporosis_drug_in_japan</guid><link>http://www.japancorp.net/press_release/24578/asahi_kasei_pharma_launches_osteoporosis_drug_in_japan</link><description>Asahi Kasei Pharma believes Teribone's efficacy in preventing fracture will make a significant contribution to the treatment of osteoporosis.</description><pubDate>Tue,6 Dec 2011 11:14:41 +0000</pubDate></item></channel></rss>

